SEC Form 4 · accession 0001209191-17-035155

G1 Therapeutics, Inc. · GTHX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

May 22, 2017

Accepted (ET)

May 24, 2017 · 7:59 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001560241

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	May 22, 2017	C	99,513	—	A	99,513	I	By L2 Ventures, LLC

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series B Preferred Stock^F1,F2,F3	—	May 22, 2017	C	172,331	D	—	—	Common Stock	57,443	0	I
Series C Preferred Stock^F1,F2,F3	—	May 22, 2017	C	126,212	D	—	—	Common Stock	42,070	0	I

F1The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis.
F2The Reporting Person is one of the general partners of Hatteras Venture Advisors V, LLC, which is the general partner of L2 Ventures, LLC. L2 Ventures, LLC is the record holder of the securities, and the Reporting Person may be deemed to share voting and dispositive power over the securities held by L2 Ventures, LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
F3The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date.